EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.

EDAP TMS S.A.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Coherus Biosciences (CHRS – Research Report), EDAP TMS (EDAP – Re...

Analysts Conflicted on These Healthcare Names: Coherus Biosciences (CHRS), EDAP TMS (EDAP) and aTyr Pharma (ATYR)

EDAP TMS ( ($EDAP) ) has issued an announcement. EDAP TMS reported a significant 49% year-over-year increase in HIFU revenue for the third quarter ...

EDAP TMS Reports Strong Q3 2025 Results and Secures EIB Credit Facility

EDAP TMS S.A. (($EDAP)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled ‘Evaluation of the Long-term...

Current Quarter	$-0.15	Next Quarter	$-0.2
Current Year	$-0.69	Next Year	$-0.71
QoQ Growth	-33.3%	YoY Growth	-2.9%
3Y EPS CAGR	+0.0%	Target Price	$5.83
Consensus	Buy	Upside	+153.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EDAP	$2.30	-2.54%	27.55K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	EDAP	$2.30	-2.5%	27.55K
3
4
5
6

EDAP

EDAP

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get EDAP TMS S.A. Data in Excel

Get EDAP TMS S.A. Data in Excel